NASDAQ$RAPT
RAPT Therapeutics Inc · Q4 2022 earnings
Q4 2022 earnings · · Investor relations
Briefing
Reported financial results for the fourth quarter and year ended December 31, 2022.
RAPT Therapeutics reported a net loss of $23.0 million for the fourth quarter of 2022, compared to a net loss of $17.9 million for the fourth quarter of 2021. The company's cash, cash equivalents and marketable securities totaled $249.1 million as of December 31, 2022, providing runway into mid-2025.
- Advanced both lead programs, RPT193 and FLX475, in inflammatory disease and cancer.
- Anticipated initiation of a Phase 2a trial with RPT193 in asthma this quarter.
- Targeting a clinical data update from ongoing Phase 2 trial of FLX475 in multiple cancer indications in the second half of this year.
- Expect topline results in mid-2024 for Phase 2b trial of RPT193 in atopic dermatitis due to slower than expected patient enrollment.
Headline financials
Revenue & EPS history
RAPT · Revenue · Quarterly
$641K
Forward guidance
RAPT Therapeutics anticipates several milestones in 2023, including the initiation of a Phase 2a trial with RPT193 in asthma and a clinical data update from the Phase 2 trial of FLX475 in multiple cancer indications. Topline results for the Phase 2b trial of RPT193 in atopic dermatitis are expected in mid-2024.
Tailwinds
- Initiation of Phase 2a trial with RPT193 in asthma this quarter.
- Clinical data update from Phase 2 trial of FLX475 in multiple cancer indications targeted for the second half of this year.
- Strong cash position expected to provide runway into mid-2025.
- Advancement of RPT193 in inflammatory disease.
- Advancement of FLX475 in cancer.
Headwinds
- Slower than expected patient enrollment in Phase 2b trial of RPT193 in atopic dermatitis.
- Topline results for Phase 2b trial of RPT193 in atopic dermatitis now expected in mid-2024.
- Net loss for the fourth quarter of 2022 was $23.0 million, compared to $17.9 million for the fourth quarter of 2021.
- Research and development expenses increased to $19.5 million for the fourth quarter of 2022, compared to $14.3 million for the same period in 2021.
- General and administrative expenses increased to $5.0 million for the fourth quarter of 2022, compared to $4.5 million for the same period in 2021.
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 8 quarterly earnings reports
-1.6%
Avg return
Earnings day
-11.5%
Avg return
5 days after
-5.0%
Avg return
30 days after
44%
11 / 25 earnings
Positive
+38.7%
Q3 2022
Best reaction
-45.8%
Q3 2020
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q4 2025 | — | — | — | |
| Q3 2025 | +2.6% | +4.5% | +21.9% | |
| Q2 2025 | +1.0% | +8.6% | +28.1% | |
| Q1 2025 | +0.0% | -8.3% | +46.2% | |
| Q4 2024 | -0.9% | +0.9% | -6.2% | |
| Q3 2024 | -10.3% | -37.1% | -41.7% | |
| Q2 2024 | -5.8% | +2.5% | -23.3% | |
| Q1 2024 | -45.7% | -50.1% | -51.8% | |
| Q4 2023 | -0.7% | -13.0% | -13.6% | |
| Q3 2023 | +8.2% | — | — | |
| Q2 2023 | -4.8% | — | — | |
| Q1 2023 | -3.5% | — | — | |
| Q4 2022 | -28.4% | — | — | |
| Q3 2022 | +38.7% | — | — | |
| Q2 2022 | +18.7% | — | — | |
| Q1 2022 | +9.7% | — | — | |
| Q4 2021 | +9.2% | — | — | |
| Q3 2021 | -1.9% | — | — | |
| Q2 2021 | -0.4% | — | — | |
| Q1 2021 | -4.0% | — | — | |
| Q4 2020 | +12.0% | — | — | |
| Q3 2020 | -45.8% | — | — | |
| Q2 2020 | +12.3% | — | — | |
| Q1 2020 | +3.7% | — | — | |
| Q4 2019 | +8.7% | — | — | |
| Q3 2019 | -12.3% | — | — | |
| Q2 2019 | — | — | — | |
| Q1 2019 | — | — | — | |
| Q4 2018 | — | — | — | |
| Q3 2018 | — | — | — | |
| Q2 2018 | — | — | — | |
| Q1 2018 | — | — | — |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro